ERBB2 and germ cell tumor: A phase I clinical trial that will assess the efficacy of HER-2-specific CAR-T Cell locoregional immunotherapy in patients with HER2-positive recurrent or refractory pediatric CNS tumors (NCT03500991), including germ cell tumors, is currently in the recruitment phase.